



**ONCONOVA**  
THERAPEUTICS

## **Onconova Therapeutics to Present at the Guggenheim Oncology Conference**

February 2, 2022

NEWTOWN, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022.

Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 10, 2022, at 8:30 a.m. ET. A webcast of the fireside chat will be available [here](#). Following the presentation, a replay will be archived on the "[Corporate Events and Presentations](#)" section of the Onconova website.

The Company will also be participating in 1x1 meetings February 9, 2022, through February 10, 2022. Meetings can be requested exclusively via Guggenheim.

### **About Onconova Therapeutics**

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova's novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova's product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit [www.onconova.com](http://www.onconova.com).

### **Company Contact:**

Avi Oler  
Onconova Therapeutics, Inc.  
267-759-3680  
[ir@onconova.us](mailto:ir@onconova.us)  
<https://www.onconova.com/contact/>

### **Investor Contact:**

Bruce Mackle  
LifeSci Advisors  
929-469-3859  
[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)